Fig. 1 · Structure
Documents & Downloads
Zerlasiran
ApoA Synthesis Reducer
Zerlasiran is an apolipoprotein A (ApoA) synthesis reducer that targets RNA to inhibit ApoA production. This compound demonstrates significant biological activity in lowering ApoA levels, making it a valuable tool in research focused on lipid metabolism and cardiovascular diseases. Zerlasiran is applicable in studies investigating the modulation of lipid profiles and the effects of reduced ApoA synthesis on atherogenesis and related conditions.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 2646703-64-0 |
| Applications | ApoA Synthesis Reducer |
| Formula | C443H594N144O277P40S10 |
| Molecular Weight | 14155.81 |
| Synonyms | SLN360 |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.